Medivie Therapeutic (Israel) Performance
| MDVI Stock | ILA 35.50 2.00 5.97% |
The company secures a Beta (Market Risk) of -0.6, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Medivie Therapeutic are expected to decrease at a much lower rate. During the bear market, Medivie Therapeutic is likely to outperform the market. At this point, Medivie Therapeutic has a negative expected return of -1.11%. Please make sure to verify Medivie Therapeutic's coefficient of variation, jensen alpha, treynor ratio, as well as the relationship between the standard deviation and total risk alpha , to decide if Medivie Therapeutic performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medivie Therapeutic has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 7.8 M | |
| Total Cashflows From Investing Activities | -4.2 M |
Medivie |
Medivie Therapeutic Relative Risk vs. Return Landscape
If you would invest 6,330 in Medivie Therapeutic on September 1, 2024 and sell it today you would lose (2,780) from holding Medivie Therapeutic or give up 43.92% of portfolio value over 90 days. Medivie Therapeutic is generating negative expected returns and assumes 4.7886% volatility on return distribution over the 90 days horizon. Simply put, 42% of stocks are less volatile than Medivie, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medivie Therapeutic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medivie Therapeutic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medivie Therapeutic, and traders can use it to determine the average amount a Medivie Therapeutic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2315
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MDVI |
Estimated Market Risk
| 4.79 actual daily | 42 58% of assets are more volatile |
Expected Return
| -1.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medivie Therapeutic is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medivie Therapeutic by adding Medivie Therapeutic to a well-diversified portfolio.
Medivie Therapeutic Fundamentals Growth
Medivie Stock prices reflect investors' perceptions of the future prospects and financial health of Medivie Therapeutic, and Medivie Therapeutic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medivie Stock performance.
| Return On Equity | -1.56 | |||
| Return On Asset | -1.09 | |||
| Operating Margin | (24.81) % | |||
| Current Valuation | 47.6 M | |||
| Shares Outstanding | 2.88 M | |||
| Price To Book | 10.59 X | |||
| Price To Sales | 71.11 X | |||
| Revenue | 491 K | |||
| EBITDA | (5.16 M) | |||
| Cash And Equivalents | 4.15 M | |||
| Cash Per Share | 1.44 X | |||
| Total Debt | 3.19 M | |||
| Debt To Equity | 0.85 % | |||
| Book Value Per Share | 1.32 X | |||
| Cash Flow From Operations | (3.88 M) | |||
| Earnings Per Share | (4.53) X | |||
| Total Asset | 12.19 M | |||
| Retained Earnings | (121 M) | |||
About Medivie Therapeutic Performance
By analyzing Medivie Therapeutic's fundamental ratios, stakeholders can gain valuable insights into Medivie Therapeutic's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Medivie Therapeutic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medivie Therapeutic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Medivie Therapeutic Limited develops and markets dental devices. Medivie Therapeutic Limited was founded in 2012 and is based in Hemel Hempstead, the United Kingdom. MEDIVIE THERP is traded on Tel Aviv Stock Exchange in Israel.Things to note about Medivie Therapeutic performance evaluation
Checking the ongoing alerts about Medivie Therapeutic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medivie Therapeutic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medivie Therapeutic generated a negative expected return over the last 90 days | |
| Medivie Therapeutic has high historical volatility and very poor performance | |
| Medivie Therapeutic has accumulated 3.19 M in total debt with debt to equity ratio (D/E) of 0.85, which is about average as compared to similar companies. Medivie Therapeutic has a current ratio of 0.64, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Medivie Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Medivie Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medivie Therapeutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medivie to invest in growth at high rates of return. When we think about Medivie Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 491 K. Net Loss for the year was (6.59 M) with loss before overhead, payroll, taxes, and interest of (603 K). | |
| Medivie Therapeutic has accumulated about 4.15 M in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Roughly 72.0% of Medivie Therapeutic outstanding shares are owned by corporate insiders |
- Analyzing Medivie Therapeutic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medivie Therapeutic's stock is overvalued or undervalued compared to its peers.
- Examining Medivie Therapeutic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medivie Therapeutic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medivie Therapeutic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medivie Therapeutic's stock. These opinions can provide insight into Medivie Therapeutic's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Medivie Stock analysis
When running Medivie Therapeutic's price analysis, check to measure Medivie Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medivie Therapeutic is operating at the current time. Most of Medivie Therapeutic's value examination focuses on studying past and present price action to predict the probability of Medivie Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medivie Therapeutic's price. Additionally, you may evaluate how the addition of Medivie Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |